Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?

Wei Shen Tan\textsuperscript{1,2}, Wei Phin Tan\textsuperscript{3}

\textsuperscript{1}Division of Surgery & Interventional Science, University College London, London, UK; \textsuperscript{2}Department of Urology, University College London Hospital, London, UK; \textsuperscript{3}Division of Urology, Rush University Medical Center, Chicago, IL, USA

Correspondence to: Wei Phin Tan, MD. Division of Urology, Rush University Medical Center, 1725 W Harrison St, Suite 348, Chicago, Illinois 60612, USA. Email: tanweiphin@yahoo.com.

Provenance: This is a Guest Editorial commissioned by Section Editor Xiao Li (Department of Urologic Surgery, The Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, China).


Submitted Nov 30, 2017. Accepted for publication Dec 12, 2017. doi: 10.21037/tau.2017.12.18

View this article at: http://dx.doi.org/10.21037/tau.2017.12.18

A non-invasive urine based biomarker that is highly sensitive and specific is the ideal test to reduce the need for cystoscopy to detect bladder cancer. This is an area of much research with proof of concept reports showing a varying level of diagnostic accuracy using protein, genomic, transcriptomic and epigenetic based markers.

In this issue of the British Journal of Urology International, Pichler and colleagues reported the diagnostic accuracy of Xpert BC Monitor (Cepheid, Sunnyvale, CA, USA) as a cross sectional prospective observational study of 140 patients having cystoscopy as part of non-muscle invasive bladder cancer (NMIBC) surveillance (1). The Xpert BC Monitor represents a point of care polymerase chain reaction (PCR) based test interrogating 5 target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10). In this study, the result of the Xpert BC Monitor was compared to urinary cytology which was evaluated using the Paris classification system, with cystoscopy representing the reference test. Pichler and colleagues report that Xpert BC Monitor had a superior overall sensitivity (84%), negative predictive value (NPV) (93%) and area under curve (0.87) compared to urinary cytology washings. In addition, sensitivity for low grade tumours was 77% although there was no difference in specificity (91%).

The Xpert BC Monitor platform is attractive for several reasons. It is a point of care test, requiring only 4 ml of urine and requires minimal hands on preparation time as it is automated. The single use disposable cartridges minimise cross contamination between different urine samples and are easy to use. With regards to its diagnostic accuracy, it successfully identified all but one high risk NMIBC (one pT1 tumour was missed) suggesting a high sensitivity. Identifying all high-risk bladder cancer is of paramount importance to allow early treatment and prevent disease progression. However, 7 of 31 low grade tumours were missed by the Xpert BC Monitor although a delay in diagnosis of these patients would pose a minimal risk (2). These results suggest a marginally better diagnostic accuracy compared to the six Food and Drug Administration (FDA) commercially approved urinary biomarkers with an overall sensitivity of 57–82% and specificity of 74–88% (3).

However, are such results sufficient to replace cystoscopy? The reason for the lack of uptake in urinary biomarker use is because none of the FDA approved tests are licensed for use as stand-alone tests without cystoscopy. The heterogeneous nature of bladder cancer suggests that a 5 panel biomarker may not be sufficient to identify all tumours (4). Other groups have reported biomarker panels ranging from 8 to 150 targets with a higher diagnostic accuracy (5,6). In addition, comparing the diagnostic ability of urinary cytology to Xpert BC Monitor serves little purpose. Urinary cytology only has value in high grade NMIBC as an adjunct to cystoscopy and not as a stand-alone test. The fact that nearly all high risk NMIBC...
were identified suggest a role in the surveillance setting to increase the interval between surveillance cystoscopies as previously suggested (7,8).

Recommendations for NMIBC surveillance vary between guidelines and incorporating urinary biomarkers will require future studies to determine the best oncologically sound and cost-effective approach (9). While Pichler and colleagues should be congratulated for their study, many groups have reported different biomarker panels with impressive results. Hence, well-designed blinded prospective observational studies are required to validate such biomarkers before wide spread adoption (10).

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References